Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia

American Journal of Hematology

Volumn 86, Issue 4, 2011, Pages 346-350

  Lee, Su Jin ^a,g   Jung, Chul Won ^a,g   Kim, Dae Young ^b,g   Lee, Kyoo Hyung ^b,g   Sohn, Sang Kyun ^c,g   Kwak, Jae Yong ^d,g   Kim, Hyeoung Joon ^e,g   Kim, In Ho ^f,g   Park, Seonyang ^f,g   Kim, Dong Hwan Dennis ^a,g  

^a Samsung Medical Center   (South Korea)

^b Asan Medical Center   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

^d Chonbuk National University Medical School   (South Korea)

^e Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^f Seoul National University Hospital   (South Korea)

^g Korean Society of Hematology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB;

ADULT; AGED; ANEMIA; ARTICLE; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE COURSE; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; LYMPHOCYTOSIS; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTOSIS; MALE; MEDICAL RECORDS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; THIAZOLES; TREATMENT OUTCOME;

EID: 79953051767     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21980     Document Type: Article

References (27)

1. Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest 2007; 117: 2067-2074.
2. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007; 370: 342-350.
3. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
4. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820.
5. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-6051.
6. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207-3213.
7. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109: 4143-4150.
8. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303-2309.
9. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood 2007; 109: 5143-5150.
10. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541.
11. Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007; 104: 13283-13288.
12. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055-4063.
13. Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008; 127: 330-339.
14. Fei F, Yu Y, Schmitt A, et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol 2008; 36: 1297-1308.
15. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366-1377.
16. Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009; 94: 135-139.
17. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23: 1398-1405.
18. Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T- and NK-cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010; 115: 772-782.
19. Rossi AR, Carluccio P, Delia M, et al. T/NK Lymphocytosis in CML Ph+ patients during Dasatinib therapy. Blood (ASH Annual Meeting Abstracts) 2009; 114: Abstract 3279.
20. Schiffer CA, Valent J. Prevalence of large granular lymphocyte proliferation in chronic myeloid leukemia (CML) patients treated with Dasatinib. Blood (ASH Annual Meeting Abstracts) 2009; 114: Abstract 1111.
21. Schiffer CA, Cortes JE, Saglio G, et al. Lymphocytosis following treatment with dasatinib is associated with improved response and outcome. J Clin Oncol (Meeting Abstracts) 2010; 28: Abstract 6553.
22. *0201, CMV reactivation and enhanced anti-leukemic control. Blood (ASH Annual Meeting Abstracts) 2009; 114: Abstract 1123.
23. Muller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations. Blood 2009; 114: 4944-4953.
24. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25: 3908-3914.
25. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26: 3204-3212.
26. Nagata Y, Ohashi K, Fukuda S, et al. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol 2010; 91: 799-807.
27. de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008; 141: 745-747.